Clinical Trial Update: Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind, placebo-controlled 18-week study evaluating linagliptin (BI 1356) added to a sulfonylurea in adults with type 2 diabetes and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2011-08-01